Blood Collection Tube for Liquid Biopsy Market

Blood Collection Tube for Liquid Biopsy Market Outlook (2025 to 2035)

The global blood collection tube for liquid biopsy market was valued at USD 157.5 million in 2025 and is forecasted to expand at a noteworthy CAGR of 19.6% to reach USD 943.4 million by 2035.

The blood collection tube market for the liquid biopsy sector will expand significantly from 2025 to 2035. Market growth arises from increasing cancer incidence worldwide and widespread interest in minimally invasive diagnostic procedures. People need early disease detection capabilities, and liquid biopsy technology continues to evolve.

The newly developed diagnostic instrument, liquid biopsy, identifies biomarkers through examination of cfDNA (cell-free DNA), CTCs (circulating tumor cells), and EVs (extracellular vesicles) found in blood and urine. Liquid biopsy has more benefits than conventional tissue biopsies: Patients experience less discomfort, doctors can monitor illness progression continuously, and mutations can be uncovered at their earliest stages. The complex blood collection tubes dedicated to liquid biopsy assist in maintaining sample integrity and ensuring accurate test outcomes.

The swift market expansion owes its success to the adoption of precision medicine, along with new biomarker detection capabilities, through technological advancements and government policies that encourage noninvasive diagnostic methods.

Metric	Value
Market Size (2020)	USD 67.5 million
Market Size (2025)	USD 157.5 million
Market Size (2035)	USD 943.4 million
Historical CAGR (2020 to 2024)	18.2%
Forecast CAGR (2025 to 2035)	19.6%

What are some of the major trends in the blood collection tube for liquid biopsy industry?

Cancer stands as a leading global cause of death, and medical practitioners identify millions of fresh cases annually. Greater mortality rates of cancer have made medical practitioners understand the prime importance of early diagnosis due to its connection with superior treatment results. The standard tissue biopsy methods demand invasive surgery because they require intensive procedures and cause difficulty during follow-up measurements. The liquid biopsy procedure establishes itself as an acceptable clinical option through easy and continuous test possibilities. The market demand for early cancer detection drives the expansion of liquid biopsy blood collection tubes due to their growing necessity for accurate and timely diagnosis.

Liquid biopsy methods have expanded their diagnostic applications to include neurodegenerative disorders, cardiovascular diseases, and infectious diseases, in addition to their primary use in cancer diagnosis. This type of medical usage drives up the market demand for dedicated blood collection tubes.

Developments in liquid biopsy technology have become substantial during the past couple of years, enhancing the accuracy of detecting disease biomarkers. Modifications made to liquid biopsy collection tubes improve the effective preservation of cfDNA, cfRNA, and CTCs, ensuring consistent diagnostic results. The sensitivity and specificity of liquid biopsy assays have increased through the combination of next-generation sequencing technology (NGS) with polymerase chain reaction technology (PCR).

The addition of vacuum-sealed tubes with innovative preservatives in their design allows researchers to stop biomarker degradation and contamination. Market growth is propelled by the continuous research and developments (R&D) focused on improving liquid biopsy efficiency.

The worldwide healthcare sector and governmental agencies allot substantial funding to liquid biopsy research because they recognize its transformative power for healthcare diagnostics. Blood collection tubes and liquid biopsy assays are being advanced through various funding programs and pharmaceutical company relationships with research facilities.

The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) established rules for liquid biopsy testing to ensure precise and dependable outcomes. This regulatory progress has grown the market and created uniform processes for applying liquid biopsy in medical practice.

What are some of the major restraints in the blood collection tube for liquid biopsy market?

The high prices of liquid biopsy tests limit their availability to developing regions because they remain financially out of reach. Small test results suffer from poor results because collection processes and analyses lack defined standard operating procedures. Many healthcare professionals and patients who live in developing areas lack knowledge about liquid biopsy advantages which prevents them from using these tests.

Biomarker stability improves through continuous technological developments in blood collection tube preservation methods, leading to better diagnostic results. The demand for targeted medicine is expanding because liquid biopsy techniques deliver precise-time analysis of disease progression, driving healthcare providers to adopt this method. Interest in applying liquid biopsy technologies extends beyond oncology. They now show promise for detecting neurodegenerative diseases, infectious diseases, and prenatal conditions, broadening their uses.

Shifts in the Blood Collection Tube for Liquid Biopsy Market: 2020 to 2024 and Future Trends 2025 to 2035

The liquid biopsy blood collection tube market expanded rapidly between 2020 and 2024 due to increased demand for noninvasive diagnostic methods, particularly for oncology purposes. The increasing world cancer statistics have fueled medical professionals' adoption of liquid biopsy instead of traditional tissue biopsy methods. The detection of circulating tumor DNA (ctDNA), circulating tumor cells (CTCs),, and extracellular vehicles (EVs) through liquid biopsy using blood draws enables more convenient early cancer screening and treatment checks.

Next-generation sequencing technology, polymerase chain reaction systems, and cell-free DNA preservation methods have driven the market expansion as fundamental growth factors. Specialized blood collection tubes that protect nucleic acids from breakdown and storage damage have significantly increased the test validity of liquid biopsies.

The market's direction from 2025 to 2035 will pivot because of expanding liquid biopsy usage beyond oncology medical applications. Researchers expect the detection of early diseases and personalized treatment to rely on liquid biopsy methods in neurology, prenatal screening, infectious disease diagnosis, and organ transplantation monitoring. The market development will be impacted by artificial intelligence (AI) based analysis, blood sample processing automation, and sustainability-focused programs.

Market Shift	2020 to 2024
Regulatory Landscape	Varied regulatory frameworks, with approvals mainly for oncology-related applications.
Technological Advancements	Improvements in cfDNA stabilization, CTC capture technologies, and NGS compatibility.
Industry-Specific Demand	Oncology (primary driver), with growing adoption in non-invasive prenatal testing (NIPT).
Sustainability & Circular Economy	Initial efforts to develop eco-friendly, plastic-free blood collection tubes.
Production & Supply Chain	Dependence on specialized suppliers, with occasional supply chain disruptions.
Market Growth Drivers	Increasing cancer burden, shift toward minimally invasive diagnostics, and improvements in biomarker research.

Market Shift	2025 to 2035
Regulatory Landscape	More stringent quality control standards and global harmonization of liquid biopsy regulations.
Technological Advancements	AI-driven liquid biopsy interpretation, automation in blood processing, and enhanced single-cell analysis.
Industry-Specific Demand	Expansion into neurology, infectious diseases, and organ transplant monitoring.
Sustainability & Circular Economy	Increased use of biodegradable and recyclable materials in tube manufacturing.
Production & Supply Chain	Localized manufacturing and AI-based predictive supply chain management.
Market Growth Drivers	Expansion of liquid biopsy applications beyond oncology and rising investment in precision medicine.

In the future, the period 2025 to 2035 will witness continued expansion into new disease indications, such as neurology, infectious diseases, and monitoring in organ transplants.

Regulatory authorities will apply higher quality requirements, forcing companies to improve product testing and validation. Artificial intelligence and automation will make biomarker identification more efficient, decreasing turnaround time for diagnoses and enhancing precision. Sustainability strategies, such as the use of biodegradable materials and a circular economy, will also revolutionize the sector.

In 2035, the market will be defined by end-to-end integration of liquid biopsy platforms infused with AI technology, enhanced diagnostic accuracy, and greater accessibility. This transformation will be pivotal for the early identification and targeted therapy of numerous conditions, making collection tubes a centerpiece of the new healthcare paradigm.

Region-wise Insights

The North American market is the leader because it combines strong healthcare infrastructure development with substantial liquid biopsy research funding and control by leading companies Guardant Health, Thermo Fisher Scientific, and Bio-Rad Laboratories. The American market features a beneficial regulatory system that supports diagnostic tests made through liquid biopsy methods. The European market continues its growth trajectory thanks to public cancer detection initiatives and IVDR compliance, which promotes innovative blood tube production.

The Asia-Pacific region is the fastest-growing market sector for this industry due to rising cancer rates, developing biotechnology sectors across China, Japan, and South Korea, and federal policies that advance precision medical applications. Market expansion results from increased knowledge about liquid biopsy's ability to replace traditional diagnostic tests.

Year	USA Attributes
Market Value (2025)	USD 60.7 Million
CAGR (2025 to 2035)	20.7%
Market value (2035)	USD 399.2 Million

Year	China Attributes
Market Value (2025)	USD 13.4 Million
CAGR (2025 to 2035)	19.2%
Market value (2035)	USD 77.7 Million

Year	Japan Attributes
Market Value (2025)	USD 4.1 Million
CAGR (2025 to 2035)	16.6%
Market value (2035)	USD 19.0 Million

Market growth will occur at double digits CAGR between 2025 to 2035 because of technological improvements along with increasing disease-specific liquid biopsy acceptance and rising diagnostic capability globally. The market shows three main trends focused on creating multi-cancer early detection (MCED) tests, adding AI and machine learning to biomarker assessment, and developing eco-friendly blood collection tubes. The diagnostic industry accelerates liquid biopsy adoption through joint research partnerships between diagnostic companies and research organizations.

Category-wise Insights

CTC (Circulating Tumor Cell) Tubes Dominate the Market Because of High Oncology Demand

CTC tubes enjoy a large market share because they play an essential role in detecting early cancer, assessing prognosis, and monitoring treatment. They are primarily used in oncology research, personalized medicine, and pharmaceutical drug development. Strict regulatory standards set by organizations like the FDA and the European Medicines Agency (EMA) guarantee product performance and reliability. There is strong demand in North America and Europe because of established healthcare infrastructure and rising cancer screening efforts.

The Application Segment of Cancer Diagnosis & Monitoring Holds the Position of Largest Size.

The oncology segment leads to market dominance because existing demand increases for noninvasive cancer testing and real-time disease status assessments. Because of their high occurrence rates, blood collection tubes that perform liquid biopsy analysis for lung, breast, prostate, and colorectal cancer detection have increased in demand. Leading market companies Guardant Health and Bio-Rad Laboratories team up with substantial U.S. research investments to drive the adoption of liquid biopsy protocols.

Non-Invasive Prenatal Testing (NIPT) Remains on the Rise despite Issues

Market expansion occurs because of rising awareness about and usage of non-invasive fetal chromosomal abnormality detection tests. Government oversight of genetic testing practices and ethical challenges related to genetic screening possibly function as market-blocking elements. The Asia Pacific region, especially China and Japan, demonstrates a rising uptake of NIPT because of improvements in healthcare regulation.

Hospitals & Diagnostic Laboratories Lead Because of Increased Patient Testing

Diagnostic labs and hospitals maintain dominant market positions due to rising requirements for cancer screening testing and NIPT. Manufacturers of automated blood collection devices invest in their development to boost operational efficiency and prevent sample contamination. The United States, Germany, and Japan maintain leadership in liquid biopsy diagnostics through well-organized healthcare institutions.

Competitive Landscape

Key players in the blood collection tube for liquid biopsy industry are Biocept Inc., F. Hoffmann-La Roche Ltd, Streck Inc., Norgen Biotek Corp, Exact Sciences Corp, MagBio Genomics Inc., Zymo Research Corporation, Apostle Sciences, QIAGEN NV, and Greiner Bio-One International GmbH among others.

Companies devote a significant portion of their revenue to R&D to resolve problems and offer creative solutions to draw in new customers and stay competitive. Companies are developing customized offerings for issues that meet industry-specific needs to compete with other players.

A high level of competition exists in the market between established global firms and emerging biotechnology companies who battle to develop innovative stabilization methods under regulatory guidelines and compatible with NGS and PCR platforms. The market competition relies on technological advances alongside regulatory requirements and acquisitions through M&A activity and geographical business expansion.

Market competition relies heavily on technological approaches that permit competitors to offer different product standpoints. Blood collection tubes for liquid biopsy need to solve three important challenges: biomarker protection, sample preservation, and efficient DNA or RNA yield for examination following analysis. Many enterprises are utilizing sophisticated stabilization reagents, vacuum-sealed tubes, and contamination-resistant coatings to strengthen their market positioning.

Technological advancements serve as the main drivers behind competitive market progress.

• A custom solution prevents nucleic acid damage by ensuring extended warehouse durations for biomarker-sensitive tests without test integrity loss.
• The use of vacuum-sealed tubes allows precise collection of measurements, which reduces both handling errors and transportation mistakes.
• Manufacturers work towards developing collection tubes that efficiently link with NGS and PCR testing frameworks.

Some organizations have established AI-driven automated analytics systems alongside French enterprises that build sample processors for liquid biopsy diagnostics. These systems boost diagnosis precision through automated biomarker identification capabilities.

Market Share Analysis by Company

Market Share Analysis by Company

Company Name	Estimated Market Share (%)
Top 5 PLayers	~45-55%
Tier II Players	~20-30%
Others	~15-25%

Strategic partnerships among tube manufacturers and diagnostics companies are defining the competitive landscape. Biocept has aligned with biotech companies to maximize the compatibility of its liquid biopsy collection solutions with molecular diagnostics platforms, thus strengthening its market positioning.

Global Expansion and Market Penetration

Although North America and Europe are still the largest markets for liquid biopsy blood collection tubes, firms are now focusing on the Asia-Pacific, Latin America, and Middle East regions due to the increasing incidence of cancer, increasing investment in biotechnology, and developing healthcare infrastructure.

China and India are fast becoming high-growth markets as government programs support early cancer screening initiatives.

Global players like Geneseeq Technology and Apostle Inc. are also aggressively developing affordable liquid biopsy solutions for Asia and Latin America, which will enable them to compete with global players.

Chinese, South Korean, and Brazilian regional biotech startups are investing in sample stabilization technologies, which is heightening competition.

Global players like Qiagen, Roche, and BD are still strengthening their distribution networks in emerging markets with robust regulatory approvals and brand names.

Key Market Players and Competitive Positioning

A combination of incumbent companies and new biotechnology companies defines the competitive landscape.

Key Attributes and Offerings by Company

Company Name	Key Offerings/Activities
Streck, Inc.	Market leader in cfDNA stabilization tubes; strong IP portfolio.
Qiagen N.V.	Offers PAXgene Blood ccfDNA Tubes; strong focus on regulatory compliance.
Roche Holding AG	Developing proprietary liquid biopsy technologies integrated with diagnostic platforms.
Biocept, Inc.	Specializes in CTC isolation and cfDNA blood collection solutions.
PreAnalytiX GmbH	BD & Qiagen JV offering FDA-cleared liquid biopsy collection tubes.
Norgen Biotek Corp.	Focus on nucleic acid stabilization and RNA-preserving tubes.
Greiner Bio-One	Offers advanced vacuum blood collection tubes for cfDNA and ctDNA.
Geneseeq Technology Inc.	Provides high-quality liquid biopsy solutions for precision oncology.
Apostle Inc.	Focus on AI-driven liquid biopsy innovations and early-stage cancer detection.

The liquid biopsy blood collection tube market is growing fast as there is mounting demand for minimally invasive cancer diagnosis, early disease detection, and precision medicine. The demand is being spurred by advances in technology for stabilizing cfDNA, ctDNA, and CTCs and growth in oncology research investments and personalized medicine.

The regulatory environment is key to defining market entry and success for manufacturers of blood collection tubes. Manufacturers with FDA (U.S.), CE (Europe), CFDA (China), and other approvals enjoy a definite market advantage since these approvals guarantee healthcare providers and diagnostic labs the reliability and safety of products.

Obtaining regulatory approvals involves comprehensive clinical validation studies, which are expensive R&D investments, laboratory trials, and compliance testing. Mature companies like Qiagen and Roche have already been able to go through this process and make their products highly accepted in clinical and research applications.

Fewer companies, in turn, face regulatory challenges that can make them go into partnership or license their technologies to other larger companies to speed up product approval and market entry.

Fact.MR has provided detailed information about the price points of key manufacturers of blood collection tube for liquid biopsy positioned across regions, sales growth, production capacity, and speculative technological expansion, in the recently published report.

Segmentation of Blood Collection Tube for Liquid Biopsy Industry Research

• By Product Type:

  • ccfDNA Tubes
  • ccfDNA Isolation Kits
  • cfRNA Tubes
  • ccfRNA Isolation Kits
  • CTC Tubes
  • gDNA Tubes
  • gDNA Isolation Kits
  • Intracellular RNA Tubes
  • Intracellular RNA Kits
  • NIPT

• By Material:

  • Glass
  • Plastic

• By Application:

  • IVD
  • Research

• End User:

  • R&D centres
  • Genetic Diagnostic Labs
  • Conventional Diagnostic Centres
  • Cancer Research Centers

• By Region:

  • North America
  • Latin America
  • Western Europe
  • Eastern Europe
  • East Asia
  • South Asia & Pacific
  • Middle East & Africa